Login
$SLN
$19.83 -$0.00 (0.03%) Live

$SLN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 10-Q
12 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 DEFA14A
12 Nov 2026 8-K: Results of Operations and Financial Condition

LONDON, Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided ...

05 Nov 2026 SCHEDULE 13G
19 Oct 2026 DEFA14A
19 Oct 2026 DEFA14A
19 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

THIS TRANSACTION AGREEMENT (this “Agreement”), dated as of October 18, 2026, is by and between MERCK KGAA, DARMSTADT, GERMANY, a German corporation with general partners (“Purchaser”), and SILENCE THERAPEUTICS PLC, a public limited compa...

13 Oct 2026 SCHEDULE 13G/A
13 Oct 2026 SCHEDULE 13G
13 Aug 2026 SCHEDULE 13D/A
13 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 Form 4: Griffiths Richard Ian, 10% owner

Acquired 5,484,320 American Depositary Shares (Open Market Sale)

12 Aug 2026 8-K: Entry into a Material Definitive Agreement; Other Events

12,962,963 AMERICAN DEPOSITARY SHARES OF THE COMPANY, EACH REPRESENTING THREE ORDINARY SHARES, NOMINAL VALUE £0.05 PER SHARE

12 Aug 2026 424B5
11 Aug 2026 S-3MEF
10 Aug 2026 424B5
10 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO

10 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support